Printer Friendly

Diagnostic Products Corporation Announces ANA Technology License Agreement with MBL.

Business Editors/Health/Medical Writers

LOS ANGELES--(BUSINESS WIRE)--May 6, 2003

Diagnostic Products Corporation (DPC) (NYSE:DP) announced that MBL of Japan has granted DPC a license to develop and commercialize diagnostic antinuclear antibody (ANA) assays on its IMMULITE(R) immunochemistry analyzers, and applications for the DPC ANA lineBlot assay.

"The combination of IMMULITE automation and the ANA technology represents a significant step forward in autoimmune testing," said Michael Ziering, President and Chief Executive Officer, DPC. "The fully automated ANA screen will offer laboratories labor savings and faster results, while follow-up testing using the ANA lineBlot and dsDNA assays will simplify the identification and monitoring of antinuclear antibodies in the patient sample. With these new tests, physicians will have a more complete clinical picture in less time and with fewer steps. Worldwide placements of the IMMULITE brand number close to 9,000 units, and the availability of fully automated ANA and dsDNA assays will make it very easy for clinical laboratories to adopt routine ANA and dsDNA testing."

By some accounts, up to 20 percent of the population is afflicted with some form of autoimmune disease, with women representing 75 percent of cases. There are approximately 80 autoimmune diseases, which collectively affect every organ in the body. Autoantibodies are associated with many systemic diseases and can be used as a diagnostic and prognostic indicator, or to monitor effectiveness of therapy.

The automated tests will be available later this year outside the United States, excluding Japan, and are slated for the United States following FDA 510k clearance. The ANA lineBlot assay is currently available outside the United States, excluding Japan. These assays are the first of DPC's growing autoimmune product line.

About Diagnostic Products Corporation

Founded in 1971, Diagnostic Products Corporation (DPC) is the global leader dedicated exclusively to immunodiagnostic testing. The Company's product menu includes over 400 tests to measure antibodies, antigens, hormones, drugs and other medically important substances present at infinitesimal concentrations in body fluids and tissues. DPC also designs and manufactures automated laboratory instrumentation which provides fast, accurate results while reducing labor and reagent costs. DPC sells its products to hospitals, clinics and laboratories domestically and in over 100 countries. Additional Company information can be found on the Company's website at www.dpcweb.com.

About MBL

MBL (http://www.mbl.co.jp), founded in 1969, is a leading Japanese manufacturer of diagnostic reagents for autoimmune diseases such as chronic rheumatoid arthritis and systemic lupus erythematosus, and has established itself as a top supplier throughout the world. Since its beginnings, MBL has focused on chronic and difficult-to-treat diseases, and has developed, manufactured and sold many related products: reagents for antinuclear antibodies for autoimmune disease screening, enzyme immunoassay reagents which detect antibody for each autoantigen, reagents that detect and confirm organ-specific antibodies, and a quantitative image analysis system.

MBL obtained the core (recombinant DNA) technology in the autoimmune testing field, developed by Dr. Jack D. Keene of Duke University, and achieved a system with consistent quality by replacing native cellular autoantigens with highly purified recombinant antigens. This system has been accepted worldwide.

Statement Under the Private Securities Litigation Reform Act

Any forward-looking statements related to the Company's expectations regarding its current and future products are subject to a number of risks and uncertainties, many of which are beyond the Company's control. These include but are not limited to, risks related to unforeseen technical obstacles in completing clinical trials, unforeseen delays in, or denials of, FDA and other regulatory approvals, future product demand and pricing performance of distributors, competitive products and technical developments, healthcare reform, and general business and economic conditions. There can be no assurance that the Company's expectations for its products will be achieved.
COPYRIGHT 2003 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:May 6, 2003
Words:616
Previous Article:Multimedia Available: HP Unveils Adaptive Enterprise Strategy to Help Businesses Manage Change and Get More from Their IT Investments.
Next Article:Viad Corp Plans Live Audio Web Access to Annual Meeting of Shareholders; Tuesday, May 13, 2003 at 9:00 a.m. Pacific Time, 12:00 noon Eastern Time.


Related Articles
Alexander Summer, LLC.
SELECTED TRADE AND PROFESSIONAL PUBLICATION, START-UPS, 2000.
MANAGEMENT Who's News PERSONNEL.
CHECKUP UCLA PROBES BREATHING, BRAIN.
Exec crafts online business licensing: government program cuts time, paper out of process. (Tech Buzz).
CD-SEM shape-sensitive linewidth measurement final report submitted.
MBL International Acquires Antibody Business from LifeSpan BioSciences.
Medical & Biological Laboratories to Sell In Vitro Diagnostics Products for Immunodiagnostic Systems.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters